1. Home
  2. ANTX

as 06-13-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Founded: 2017 Country:
United States
United States
Employees: N/A City: MENLO PARK
Market Cap: 59.4M IPO Year: 2022
Target Price: $5.00 AVG Volume (30 days): 236.6K
Analyst Decision: Hold Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.54 EPS Growth: N/A
52 Week Low/High: $1.91 - $22.22 Next Earning Date: 08-08-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

ANTX Daily Stock ML Predictions

Stock Insider Trading Activity of AN2 Therapeutics Inc. (ANTX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Adjuvant Global Health Technology Fund, L.P. ANTX 10% Owner Jan 16 '24 Sell $19.65 84,093 $1,652,427.45 1,995,958 SEC Form 4
Adjuvant Global Health Technology Fund, L.P. ANTX 10% Owner Jan 16 '24 Sell $19.65 15,907 $312,572.55 377,542 SEC Form 4
Aziz Kabeer ANTX Director Jan 16 '24 Sell $19.65 84,093 $1,652,427.45 1,995,958 SEC Form 4
Aziz Kabeer ANTX Director Jan 16 '24 Sell $19.65 15,907 $312,572.55 377,542 SEC Form 4
Readnour Robin Shane ANTX Director Jan 12 '24 Sell $21.92 706 $15,475.52 414,788 SEC Form 4
Readnour Robin Shane ANTX Director Jan 12 '24 Sell $21.91 719 $15,753.29 485,073 SEC Form 4
Readnour Robin Shane ANTX Director Jan 10 '24 Sell $21.93 1,869 $40,987.17 415,494 SEC Form 4
Readnour Robin Shane ANTX Director Jan 10 '24 Sell $21.92 1,800 $39,456.00 485,792 SEC Form 4
Krause Kevin Michael ANTX Chief Strategy Officer Jan 9 '24 Sell $20.14 7,417 $149,367.25 1,914 SEC Form 4
Krause Kevin Michael ANTX Chief Strategy Officer Jan 2 '24 Sell $20.12 2,583 $51,967.12 1,914 SEC Form 4
Easom Eric ANTX Chief Executive Officer Jan 2 '24 Sell $20.09 2,777 $55,802.43 2,130 SEC Form 4
Adjuvant Global Health Technology Fund, L.P. ANTX 10% Owner Nov 14 '23 Sell $16.15 1,522 $24,574.21 2,080,051 SEC Form 4
Adjuvant Global Health Technology Fund, L.P. ANTX 10% Owner Nov 14 '23 Sell $16.15 288 $4,650.05 393,449 SEC Form 4

Share on Social Networks: